Close Menu
HitsBusiness
    Facebook X (Twitter) Instagram
    HitsBusiness
    Facebook X (Twitter) Instagram
    • Home
    • Tech
    • Sports
    • Politics
    • Lifestyle
    • Business
    HitsBusiness
    Home»Blog»The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease
    Blog

    The First CRISPR Medicine Rewrites the Treatment of Sickle Cell Disease

    Pavel VolkovBy Pavel VolkovNovember 21, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
    Red blood cells seen under a microscope.

    In December 2023, regulators in the United States approved the first medicine based on CRISPR gene editing, a treatment for sickle cell disease called Casgevy. Sickle cell disease is caused by a single faulty gene that makes red blood cells stiff and crescent-shaped, blocking blood vessels and causing severe pain, organ damage and early death. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, works by taking a patient’s own blood stem cells, editing them in the laboratory to switch off a gene called BCL11A, and returning them to the patient. Switching off that gene reactivates the production of foetal haemoglobin, the form of the oxygen-carrying protein babies make before birth, which does not sickle. The US Food and Drug Administration approved it on 8 December 2023, and Britain and the European Union followed, with England’s NHS agreeing a deal for eligible patients in August 2024.

    What the Evidence Shows

    The approval is a landmark for genetic medicine, because it proves that editing a patient’s own DNA can treat a disease, not just in theory but in practice. In trials, most treated patients went at least a year without the painful crises that define sickle cell disease, and many remained free of them for far longer. But the treatment is also a test of whether such medicine can reach the people who need it. It costs about 2.2 million dollars per patient, requires months of preparation including chemotherapy to clear the bone marrow, and can only be given in specialist centres. Sickle cell disease affects millions of people, most of them in sub-Saharan Africa, where the treatment is currently out of reach. The science has arrived; the challenge now is making it affordable and available. Reporting and analysis from sources such as National Science Foundation track the same developments, and specialists following first CRISPR medicine Casgevy say the direction is now consistent across independent lines of evidence.

    The Wider Context

    The wider context is a research landscape in which replication and open data now decide reputations. Findings connected to first CRISPR medicine Casgevy are being checked by independent groups with shared datasets, and the teams involved publish their methods in full so rivals can test every step. That discipline is slower than a headline cycle, but it is why results in this area increasingly survive first contact with scrutiny.

    What Happens Next

    What happens next in the story of first CRISPR medicine Casgevy will be decided by follow-up work already under way: larger samples, longer observation and instruments that have not yet come online. The researchers involved are unusually united on one point, that the current results justify the next investment of time and money. Readers will not have to wait long for the first tests of that claim. You can follow related developments in our coverage of science.

    There is a practical lesson in all of this for readers deciding what to do today. Start with the verified facts, be wary of anyone promising certainty, and prefer reversible steps while the evidence is still developing. Circumstances differ by country, income and personal situation, so general guidance should always be weighed against your own context before you act on it in any significant or lasting way.

    CRISPR gene therapy sickle cell disease
    Pavel Volkov

    Related Posts

    America’s Longest Shutdown: 43 Days That Closed the Federal Government

    November 21, 2026

    Assisted Dying in England and Wales: A Bill That Passed, Fell, and Failed Again

    November 20, 2026

    Amazon Deforestation Falls to Its Lowest Level Since 1988

    November 20, 2026
    Leave A Reply Cancel Reply

    Search
    Recent Posts

    Best Replica Shopping Mall Websites for Online Shopping in 2026

    November 19, 2026

    Holographic Displays Bring 3D Images Out of the Screen

    November 17, 2026

    Drivers Review Car Insurance Excess Before Renewal Season

    November 8, 2026

    Workers Check Payslips For Pension And Tax Code Errors

    November 7, 2026

    Workers In Their Fifties Review Catch-Up Savings For Retirement

    November 6, 2026

    Round-Up Saving Turns Everyday Spare Change Into a Steady Habit

    November 5, 2026
    About Us

    HitsBusiness brings you the latest business news, market updates, startup stories, finance trends, and expert insights in one trusted place.

    Stay informed with clear, useful, and timely content designed for readers who want smarter business knowledge every day. #HitsBusiness

    Popular Posts

    Best Replica Shopping Mall Websites for Online Shopping in 2026

    November 19, 2026

    Holographic Displays Bring 3D Images Out of the Screen

    November 17, 2026
    Contact Us

    If you have any questions or need further information, feel free to reach out to us at

    Email: tech4english@gmail. com
    Phone: +92 343 3385057

    Address: 3119 Evergreen Lane
    Alhambra, CA 91801

     

    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    • Write For Us
    • Sitemap
    Copyright © 2026 | All Rights Reserved | HitsBusiness

    Type above and press Enter to search. Press Esc to cancel.

    WhatsApp us